Melanoma News and Research

Latest Melanoma News and Research

Einstein faculty members present recent research at AACR Annual Meeting

From uncovering the role nerve cells play in metastasis to identifying new cancer-causing genes, researchers at Albert Einstein College of Medicine of Yeshiva University made notable advances in the understanding and potential treatment of cancer during the past year.

29 Mar 2014

MD Anderson's Jim Allison honored with 2014 Canada Gairdner International Award

A Canadian institution that annually recognizes seminal medical discoveries selected cancer immunotherapy leader Jim Allison, Ph.D., chair and professor of Immunology at The University of Texas MD Anderson Cancer Center, for one of its 2014 Canada Gairdner International Awards.

29 Mar 2014

Senhwa Biosciences to present CX-5461 study results at AACR meeting

Senhwa Biosciences, Inc. announced today that results from research with its first-in-class Pol I inhibitor, CX-5461, will be presented at the 2014 American Association for Cancer Research (AACR) annual meeting held on April 5-9 in San Diego, CA.

27 Mar 2014

Johns Hopkins researchers use 3-D MRI scans to accurately measure tumor viability and death

In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized 3-D MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy - delivered directly through a tumor's blood supply - is working.

27 Mar 2014

EKF Molecular to exhibit PointMan DNA-enrichment technology at AACR 2014

EKF Diagnostics, the global in vitro diagnostics business, will be present on Booth #438 at AACR 2014, 5-9th April, San Diego.

From EKF Diagnostics 26 Mar 2014

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Adaptimmune today announced that it has been awarded a grant of £2.1 million from the Biomedical Catalyst Fund, managed by the UK’s innovation agency the Technology Strategy Board and the Medical Research Council. The prestigious award will expedite the development of Adaptimmune’s second engineered T cell therapy programme into the clinic in triple negative breast cancer.

26 Mar 2014

Cell-free DNA analysis allows noninvasive tumour genotype monitoring

Noninvasive tumour genotyping using cell-free plasma DNA analysis is feasible, say US researchers who believe the technique will aid patient diagnosis and monitoring.

24 Mar 2014

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an overview of its three clinical development programs and Year for the year ended December 31, 2013.

24 Mar 2014

ZL105 drug could potentially replace currently used anticancer drugs, study finds

A revolution in cancer treatment could soon be underway following a breakthrough that may lead to a dramatic improvement in cancer survival rates.

21 Mar 2014

Endomagnetics receives award for Best New Product

Endomagnetics, the company enjoying international commercial success with its medical device technology, has been given the award for Best New Product or Business Model in this year’s Business Weekly awards. The award was made at a gala dinner at Queens’ College, Cambridge last night.

20 Mar 2014

Researchers uncover new connection between allergy and cancer

While many are stocking up on allergy medicine in preparation for spring, a new study from researchers at Virginia Commonwealth University Massey Cancer Center has uncovered a new connection between allergy and cancer that could potentially lead to therapies involving common antihistamines.

20 Mar 2014

Genomic analysis to study cancer in dogs can help develop new therapies for human cancers

Using genomic analysis to study cancer in dogs can help develop new therapies for humans with cancer, according to a proof-of-concept study led by the National Cancer Institute (NCI) and the Translational Genomics Research Institute (TGen).

19 Mar 2014

Added benefit of ipilimumab in advanced melanoma not proven for non-pretreated patients

The German Institute for Quality and Efficiency in Health Care already assessed the added benefit of ipilimumab in advanced melanoma in 2012. A considerable added benefit was found for patients who had already received previous treatment. In the new dossier compiled by the drug manufacturer, the drug was now compared with the appropriate comparator therapy dacarbazine specified by the Federal Joint Committee (G-BA) also for non-pretreated patients.

19 Mar 2014

MD Anderson collaborates with MedImmune to develop therapies that unleash patients' immune systems to attack cancers

The University of Texas MD Anderson Cancer Center and MedImmune, the global biologics research and development arm of AstraZeneca, will collaborate through MD Anderson's Moon Shots Program to develop therapies that unleash patients' immune systems to attack their cancers.

14 Mar 2014

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

PhotoMedex, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2013.

13 Mar 2014

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, today announced a strategic immuno-oncology collaboration with TESARO, Inc., an oncology-focused biopharmaceutical company.

13 Mar 2014

iCAD prices underwritten public offering of 2,400,000 shares of common stock

iCAD, Inc. ("iCAD"), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy solutions for the early identification and treatment of cancer, today announced it has priced a registered firm commitment underwritten public offering of 2,400,000 shares of its common stock at a price to public of $11.00 per share.

12 Mar 2014

Rexahn reports initial results from Supinoxin Phase I trial in patients with solid cancer tumors

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company announced today initial data for the Phase I dose-escalation clinical trial of SupinoxinTM (RX-5902) initiated in August 2013. This trial was designed to study safety and efficacy in patients with solid cancer tumors.

11 Mar 2014

Scientists discover new protein that drive metastasis of cancer cells

An international team of researchers led by scientists at The Wistar Institute have discovered and defined LIMD2, a protein that can drive metastasis, the process where tumors spread throughout the body.

11 Mar 2014

Sentinel node biopsy increases survival rates in melanoma patients

Moffitt Cancer Center researchers have been instrumental in making significant improvements to the diagnostic procedure called sentinel node biopsy for melanoma patients and teaching this procedure to physicians from around the world.

10 Mar 2014

Melanoma News and Research

Latest Melanoma News and Research

Einstein faculty members present recent research at AACR Annual Meeting

MD Anderson's Jim Allison honored with 2014 Canada Gairdner International Award

Senhwa Biosciences to present CX-5461 study results at AACR meeting

Johns Hopkins researchers use 3-D MRI scans to accurately measure tumor viability and death

EKF Molecular to exhibit PointMan DNA-enrichment technology at AACR 2014

Adaptimmune awarded £2.1 million grant to expedite development of engineered T cell therapy

Cell-free DNA analysis allows noninvasive tumour genotype monitoring

Rexahn provides updates on clinical development programs, reports full-year 2013 financial results

ZL105 drug could potentially replace currently used anticancer drugs, study finds

Endomagnetics receives award for Best New Product

Researchers uncover new connection between allergy and cancer

Genomic analysis to study cancer in dogs can help develop new therapies for human cancers

Added benefit of ipilimumab in advanced melanoma not proven for non-pretreated patients

MD Anderson collaborates with MedImmune to develop therapies that unleash patients' immune systems to attack cancers

PhotoMedex Q4 2013 revenues up 16% to $63.5 million

AnaptysBio announces strategic immuno-oncology collaboration with TESARO

iCAD prices underwritten public offering of 2,400,000 shares of common stock

Rexahn reports initial results from Supinoxin Phase I trial in patients with solid cancer tumors

Scientists discover new protein that drive metastasis of cancer cells

Sentinel node biopsy increases survival rates in melanoma patients

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Melanoma News and Research

Latest Melanoma News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in